Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial Prospectively collected ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results